dc.contributor.author | Hızal, Mutlu | |
dc.contributor.author | Bilgin, Burak | |
dc.contributor.author | Paksoy, Nail | |
dc.contributor.author | Kılıçkap, Sadettin | |
dc.contributor.author | Atcı, Muhammed Mustafa | |
dc.contributor.author | Kahraman, Seda | |
dc.contributor.author | Keskinkılıç, Merve | |
dc.contributor.author | Bilgetekin, İrem | |
dc.contributor.author | Ayhan, Murat | |
dc.contributor.author | Tural, Deniz | |
dc.contributor.author | Eren, Önder | |
dc.contributor.author | Akkoç Mustafayev, Fatma Nihan | |
dc.contributor.author | Yaman, Şebnem | |
dc.contributor.author | Tatlı, Ali Murat | |
dc.contributor.author | Bayram, Ertuğrul | |
dc.contributor.author | Kutlu, Yasin | |
dc.contributor.author | Ertürk, İsmail | |
dc.contributor.author | Özcan, Erkan | |
dc.contributor.author | Gülmez, Ahmet | |
dc.contributor.author | Korkmaz, Mustafa | |
dc.contributor.author | Akagündüz, Baran | |
dc.contributor.author | Erdem, Dilek | |
dc.contributor.author | Akın Telli, Tuğba | |
dc.contributor.author | Aksoy, Asude | |
dc.contributor.author | Üskent, Necdet | |
dc.contributor.author | İriağaç, Yakup | |
dc.contributor.author | Köse Baytemür, Naziyet | |
dc.contributor.author | Aydın, Dinçer | |
dc.contributor.author | Sakalar, Teoman | |
dc.contributor.author | Arak, Haci | |
dc.contributor.author | Selçukbiricik, Fatih | |
dc.contributor.author | Ergün, Yakup | |
dc.contributor.author | Korkmaz, Taner | |
dc.contributor.author | Ak, Naziye | |
dc.contributor.author | Ünal, Çağlar | |
dc.contributor.author | Akdeniz, Nadiye | |
dc.contributor.author | Özgün, Mehmet Alpaslan | |
dc.contributor.author | Öksüzoğlu, Berna | |
dc.contributor.author | Yalçın, Bülent | |
dc.contributor.author | Öztop, İlhan | |
dc.contributor.author | Algın, Efnan | |
dc.contributor.author | Sakin, Abdullah | |
dc.contributor.author | Aydıner, Adnan | |
dc.contributor.author | Yumuk, Perran Fulden | |
dc.contributor.author | Şendur, Mehmet Ali Nahit | |
dc.date.accessioned | 2022-07-29T07:34:59Z | |
dc.date.available | 2022-07-29T07:34:59Z | |
dc.date.issued | 2022 | en_US |
dc.identifier.citation | Hızal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S. ... Şendur, M. A. N. (2022). Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study. Future Oncology, 18(23), 2573-2582. https://doi.org/10.2217/fon-2022-0083 | en_US |
dc.identifier.issn | 1479-6694 | |
dc.identifier.issn | 1744-8301 | |
dc.identifier.uri | https://doi.org/10.2217/fon-2022-0083 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/9620 | |
dc.description.abstract | Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with first-line alectinib in terms of ALK-tyrosine kinase inhibitors, regardless of previous chemotherapy. The co-primary end points were progression-free survival both for all patients and for the treatment-naive population. The secondary end points were overall response rate, overall survival, rate of CNS progression and safety. Results & conclusion: A total of 274 patients (n = 177 for treatment-naive patients) were enrolled in the study. The median progression-free survival was 26 and 28.8 months for all patients and the treatment-naive group, respectively. The overall response rate, CNS progression rate and 1-year overall survival ratio were 77.9, 12.4 and 77%. Alectinib is a highly effective therapy with a favorable safety profile. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Future Medicine Ltd. | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Alectinib | en_US |
dc.subject | ALK | en_US |
dc.subject | First-Line | en_US |
dc.subject | Non-Small-Cell Lung Cancer | en_US |
dc.subject | Real-World | en_US |
dc.title | Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Future Oncology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0003-2184-634X | en_US |
dc.identifier.volume | 18 | en_US |
dc.identifier.issue | 23 | en_US |
dc.identifier.startpage | 2573 | en_US |
dc.identifier.endpage | 2582 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.2217/fon-2022-0083 | en_US |
dc.institutionauthor | Kutlu, Yasin | |
dc.identifier.wosquality | Q3 | en_US |
dc.identifier.wos | 000814515100001 | en_US |
dc.identifier.scopus | 2-s2.0-85134156033 | en_US |
dc.identifier.pmid | 35734870 | en_US |
dc.identifier.scopusquality | Q2 | en_US |